The science behind
every conversation.
ReMemo isn't just a chatbot. Every interaction is a structured clinical observation, powered by four layers of on-device intelligence that detect the subtle signals of cognitive change long before they become obvious.
4
Analytical layers
100%
On-device processing
0
Data to the cloud
6+
Years ahead of symptoms
Live lexical analysis
Roses were everywhere that summer. I hadforty varieties in the garden— the Cecile Brunners were my favourites.
8
Concrete nouns
4
Spatial words
3
Temporal markers
Lexical Categorization
Language is a window into cognition. ReMemo analyses every utterance across multiple semantic dimensions — tracking not just what is said, but how it is said.
Vocabulary richness (TTR)
The type-token ratio measures how varied language is — a declining TTR is an early marker of cognitive load.
Category fluency
How easily a person generates items within a category (animals, foods, places) is strongly correlated with executive function.
Semantic coherence
Topic drift and incoherence — measured via sentence embedding similarity — signal subtle disruptions in working memory.
Temporal language markers
Misuse of tense, confusion of past/present, or loss of time anchoring are flagged and tracked longitudinally.
Voice Pattern ML
The voice carries information the words alone cannot. Research shows that vocal biomarkers can detect cognitive decline up to 6 years before a formal diagnosis.
Prosodic feature extraction
Pitch variation, speech rate, rhythm, and energy envelope are extracted per utterance using CoreML audio models.
Pause pattern analysis
Increased within-sentence pauses and extended inter-word gaps are associated with lexical access difficulties.
Articulation rate monitoring
Slowing of articulation rate is one of the earliest and most consistent biomarkers of neurodegenerative change.
Personalised baseline
The first 14 days establish each user's unique vocal profile. All subsequent analysis is relative to this personal baseline — not a population average.
Voice analysis
On-deviceSpeech rate
142 wpm
−4% vs baseline
Pause ratio
18%
+2% vs baseline
Pitch variation
32 Hz
Within normal
Articulation
Normal
No change detected
On-Device Apple Intelligence
This is not a commitment we make in a privacy policy and then forget. It is an architectural constraint. The data literally cannot leave the device.
Apple Neural Engine
All inference — speech analysis, language modeling, trend detection — runs exclusively on the A-series chip's Neural Engine.
Encrypted Local Storage
Conversations, memories, and analysis results are stored in an AES-256 encrypted local vault. Only the device owner holds the key.
Zero Cloud Architecture
No analytics pipeline. No telemetry. No model training on user data. The app functions fully offline, always.
The Privacy Promise
We will never train models on your family's data. We will never sell or share it. We will never move it to the cloud. GDPR compliant by design, not by policy. In full compliance with EU MDR 2017/745 and HIQA standards for care technology.
Longitudinal score
Margaret — 12 weeks
70
Baseline
Week 1–2
81
Current
This week
↑ +16%
Trend
vs baseline
Longitudinal Analysis
A single conversation tells you little. A hundred conversations, measured the same way, tell you everything. ReMemo is designed for the long game.
Personalised baseline (Day 1–14)
The first two weeks establish the individual's cognitive and linguistic baseline — setting the reference point for all future measurements.
Weekly trend detection
Statistical models flag deviations from the baseline that exceed normal variance — distinguishing a bad day from a meaningful change.
Clinician-ready reports
Summarised weekly or monthly reports can be exported as PDF and shared directly with a GP, neurologist, or care team.
Early intervention window
Research from Boston University shows vocal biomarkers can surface cognitive changes 6+ years before clinical diagnosis — ReMemo acts in this window.
Medical disclaimer: ReMemo is a wellness and companionship tool. It is not a medical device and does not diagnose, treat, or prevent any disease, including Alzheimer's Disease. It operates in compliance with EU MDR 2017/745 Rule 11 as a non-regulated wellness application. Data interpretations are informational and should always be discussed with a qualified healthcare provider.
Want to see it in action?
Join our pilot waitlist and be among the first families to experience ReMemo.